FULCRUM THERAPEUTICS

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023

15 May 2023 07:05:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer

15 May 2023 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET

08 May 2023 16:05:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 May 2023 18:06:50 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Apr 2023 17:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces CFO Resignation

05 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Mar 2023 17:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

09 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET

06 Mar 2023 16:05:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease

24 Feb 2023 08:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Feb 2023 17:27:22 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference

08 Feb 2023 17:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

17 Jan 2023 23:15:16 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock

17 Jan 2023 16:01:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 Jan 2023 17:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Provides Business Update and 2023 Outlook

04 Jan 2023 07:02:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces CEO Transition

04 Jan 2023 07:01:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Dec 2022 17:20:59 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference

01 Dec 2022 16:01:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Nov 2022 18:33:20 By Nasdaq GlobeNewswire